Figure 6 — RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway | Aging

Navigate

Submit an Article

Research Paper|Volume 16, Issue 17|pp. 12392–12413

RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway

Back to articleFigure 6(6 of 11)

100%

Figure 6.The expression of RPL22L1 was related to immune infiltration in LUAD single cells.